Wikiversity

Progress and Prospects in Parkinson's Research/Therapy/Neuroprotection/Quinoxaline

< Progress and Prospects in Parkinson's Research | Therapy | Neuroprotection

The antioxidant properties of quinoxaline have yet to be evaluated fully

Background

edit

Quinoxaline (NBQX)is also called a benzopyrazine, in organic chemistry, and is a heterocyclic compound containing a ring complex made up of a benzene ring and a pyrazine ring. It is isomeric with quinazoline, phthalazine and cinnoline.

Research

edit

2009


Faust et al [1] carried out a series of tests on fruit flies.

In the present study, a Drosophila DJ-1A model of PD was used to test potential neuroprotective drugs. The drugs applied are the Chinese herb celastrol, the antibiotic minocycline, the bioenergetic amine coenzyme Q10 (coQ10), and the glutamate antagonist 2,3-dihydroxy-6-nitro-7-sulphamoylbenzo[f]-quinoxaline (NBQX). All of these drugs target pathogenic processes implicated in PD, thus constitute mechanism-based treatment strategies. We show that celastrol and minocycline, both having antioxidant and anti-inflammatory properties, confer potent dopaminergic neuroprotection in Drosophila DJ-1A model, while coQ10 shows no protective effect. NBQX exerts differential effects on cell survival and brain dopamine content: it protects against DN loss but fails to restore brain dopamine level.

Further Reading

edit

Today

Use the following links to query the PubMed, PubMed Central and Google Scholar databases using the Search terms:- Parkinson's_Disease Quinoxaline.

This will list the latest papers on this topic. You are invited to update this page to reflect such recent results, pointing out their significance.

Pubmed (abstracts)

Pubmed_Central (Full_Text)

Google_Scholar

edit

Therapy > Neuroprotection

Sub Pages:

Neuroprotective agents
Substances with possible neuroprotective properties:
Caffeine,--Celastrol,--Co-Enzyme Q10,--Creatine,--DHA,--Exendin-4 (EX-4),--GDNF,--Glutathione (GSH),--GM1,--Isradipine,--Melatonin,--Minocycline,--Nicotine,--NSAIDs,--Phenylbutyrate,--Phytic Acid,--Probucol,--Quinoxaline,--Rasagiline,--Riboflavin,--Statins,--Tolcapone,--Urate & Uric Acid,--Vitamin D,--Vitamin E,--

References

edit

<references>

  1. ↑ Faust, K,; Gehrke, S.; Yang, Y.; Yang, L.; Beal M. F. and Lu, B. (2009) Full Text BMC Neurosci. 10:109. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152779/?tool=pmcentrez
Retrieved from "https://en.wikiversity.org/w/index.php?title=Progress_and_Prospects_in_Parkinson%27s_Research/Therapy/Neuroprotection/Quinoxaline&oldid=2109131"